These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 1595521)

  • 1. Effects of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, in preventing restenosis after percutaneous transluminal coronary angioplasty.
    Okamoto S; Inden M; Setsuda M; Konishi T; Nakano T
    Am Heart J; 1992 Jun; 123(6):1439-44. PubMed ID: 1595521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, reduces restenosis after percutaneous transluminal coronary angioplasty. Results of the randomized, double-blind STARC study. Studio Trapidil versus Aspirin nella Restenosi Coronarica.
    Maresta A; Balducelli M; Cantini L; Casari A; Chioin R; Fabbri M; Fontanelli A; Monici Preti PA; Repetto S; De Servi S
    Circulation; 1994 Dec; 90(6):2710-5. PubMed ID: 7994812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The trapidil restenosis trial (STARC study): background, methods and clinical characteristics of the patient population.
    Maresta A; Balducelli M; Cantini L; Casari A; Chioin R; Fontanelli A; Monici Preti PA; Repetto S; Raffaghello S
    Clin Trials Metaanal; 1994 Apr; 29(1):31-40. PubMed ID: 10150183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized comparison of trapidil (triazolopyrimidine), a platelet-derived growth factor antagonist, versus aspirin in prevention of angiographic restenosis after coronary artery Palmaz-Schatz stent implantation.
    Galassi AR; Tamburino C; Nicosia A; Russo G; Grassi R; Monaco A; Giuffrida G
    Catheter Cardiovasc Interv; 1999 Feb; 46(2):162-8. PubMed ID: 10348536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
    Maresta A; Balducelli M; Latini R; Bernardi G; Moccetti T; Sosa C; Barlera S; Varani E; Ribeiro da Silva EE; Monici Preti A; Maggioni AP;
    Catheter Cardiovasc Interv; 2005 Mar; 64(3):375-82. PubMed ID: 15736248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty.
    Corcos T; David PR; Val PG; Renkin J; Dangoisse V; Rapold HG; Bourassa MG
    Am Heart J; 1985 May; 109(5 Pt 1):926-31. PubMed ID: 3158187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early decrease in minimal luminal diameter after successful percutaneous transluminal coronary angioplasty predicts late restenosis.
    Rodriguez A; Santaera O; Larribeau M; Sosa MI; Palacios IF
    Am J Cardiol; 1993 Jun; 71(16):1391-5. PubMed ID: 8517382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial.
    Yokoi H; Daida H; Kuwabara Y; Nishikawa H; Takatsu F; Tomihara H; Nakata Y; Kutsumi Y; Ohshima S; Nishiyama S; Seki A; Kato K; Nishimura S; Kanoh T; Yamaguchi H
    J Am Coll Cardiol; 1997 Oct; 30(4):855-62. PubMed ID: 9316509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit.
    Liu MW; Roubin GS; Robinson KA; Black AJ; Hearn JA; Siegel RJ; King SB
    Circulation; 1990 Mar; 81(3):1089-93. PubMed ID: 2137730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restenosis after successful percutaneous transluminal coronary angioplasty: the Montreal Heart Institute experience.
    Guiteras Val P; Bourassa MG; David PR; Bonan R; Crépeau J; Dyrda I; Lespérance J
    Am J Cardiol; 1987 Jul; 60(3):50B-55B. PubMed ID: 2956844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Residual platelet function under acetylsalicylic acid and the risk of restenosis after coronary angioplasty.
    Terres W; Hamm CW; Ruchelka A; Weilepp A; Kupper W
    J Cardiovasc Pharmacol; 1992 Feb; 19(2):190-3. PubMed ID: 1376787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic response to gain and loss in coronary minimal luminal diameter in patients treated with coronary angioplasty: prediction of restenosis on the basis of exercise capacity.
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Egeland T; Thaulow E
    Am Heart J; 2000 Mar; 139(3):482-90. PubMed ID: 10689263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
    Schwartz L; Lesperance J; Bourassa MG; Eastwood C; Kazim F; Arafah M; Ganassin L
    Am Heart J; 1990 Feb; 119(2 Pt 1):232-6. PubMed ID: 2405609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty.
    Barnathan ES; Schwartz JS; Taylor L; Laskey WK; Kleaveland JP; Kussmaul WG; Hirshfeld JW
    Circulation; 1987 Jul; 76(1):125-34. PubMed ID: 2954724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors of restenosis after multivessel percutaneous transluminal coronary angioplasty.
    Le Feuvre C; Bonan R; Lespérance J; Gosselin G; Joyal M; Crépeau J
    Am J Cardiol; 1994 May; 73(12):840-4. PubMed ID: 8184804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.